Page last updated: 2024-12-08
furimidazoline
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
furimidazoline: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 456460 |
| CHEMBL ID | 58173 |
| SCHEMBL ID | 549282 |
| MeSH ID | M0331537 |
Synonyms (10)
| Synonym |
|---|
| 2-[4-[5-[4-(4,5-dihydro-1h-imidazol-2-yl)phenyl]-2-furyl]phenyl]-4,5-dihydro-1h-imidazole |
| furan der. |
| 2,5-bis[4-imidazolinphenyl]-furan |
| furimidazole |
| furimidazoline |
| CHEMBL58173 |
| 1h-imidazole, 2,2'-(2,5-furandiyldi-4,1-phenylene)bis[4,5-dihydro- |
| 80498-71-1 |
| SCHEMBL549282 |
| DTXSID20332431 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (7)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID340909 | Binding affinity to Clostridium perfringens genomic DNA assessed as decrease in fluorescence intensity at 1 uM by fluorescence spectral method relative to control | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes. |
| AID340904 | Binding affinity to poly(dA).poly(dT) assessed as increase in melting temperature | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes. |
| AID340905 | Binding affinity at d(CGCGAATTCGCG) synthetic oligomer duplex assessed as increase in melting temperature | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes. |
| AID38040 | Drug concentration required to inhibit B16 cell growth by 50% after 72 hours of incubation | 2002 | Journal of medicinal chemistry, May-09, Volume: 45, Issue:10 | Distribution of furamidine analogues in tumor cells: influence of the number of positive charges. |
| AID478754 | Binding affinity to d(CGCGAATTCGCG)2 dodecamer assessed as change in melting temperature | 2010 | European journal of medicinal chemistry, May, Volume: 45, Issue:5 | Theoretical models of pentamidine analogs activity based on their DNA minor groove complexes. |
| AID340902 | Antitrypanosomal activity against Trypanosoma brucei brucei S427 after 72 hrs | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes. |
| AID340903 | Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB900 after 72 hrs | 2007 | Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8 | Diphenyl furans and aza analogs: effects of structural modification on in vitro activity, DNA binding, and accumulation and distribution in trypanosomes. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.82
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.82) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||